Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure

Circulation. Heart Failure
Veselin MitrovicBerthold Hocher

Abstract

Blocking the tubuloglomerular feedback mechanism with adenosine A1 receptor antagonists seems to improve diuresis and sodium excretion without compromising the glomerular filtration rate in patients with heart failure. However, the direct cardiac effects of this compound class have not been investigated to date. In total, 111 patients (109 men and 2 women) received a 1-hour infusion of 5, 10, and 15 mg SLV320, an adenosine A1 receptor antagonist, placebo, or 40 mg furosemide. Mean age was 57.9 years, mean ejection fraction was 28.1%, 82 patients were of New York Heart Association class II, and 29 patients were of New York Heart Association class III. Hemodynamic parameters (heart rate, blood pressure, pulmonary capillary wedge pressure, mean pulmonary arterial pressure, systemic vascular resistance, right atrial pressure, and cardiac output) were determined. Kidney function was assessed by cystatin C measurements and by analysis of urine output and urine electrolytes. In addition, pharmacokinetics of SLV320 and ex vivo inhibition of adenosine A1 receptor activity were performed. SLV320 was well tolerated, and no serious adverse events were observed. Heart rate, blood pressure, pulmonary capillary wedge pressure, mean pulmonary ...Continue Reading

References

Dec 1, 1994·Biological & Pharmaceutical Bulletin·T YamagataA Karasawa
Apr 15, 1999·Journal of the American Society of Nephrology : JASN·C S WilcoxL Belardinelli
Jan 3, 2001·Kidney International·Y RenO A Carretero
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·J Linden
Mar 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Martin Bak, Klaus Thomsen
Dec 2, 2004·Clinical Nephrology·A AhlströmV Pettilä
Jan 18, 2005·Journal of the American College of Cardiology·Michael G ShlipakMark J Sarnak
Mar 19, 2005·Critical Care : the Official Journal of the Critical Care Forum·Patricia VillaPilar Casasnovas
Apr 26, 2005·The American Journal of Cardiology·Steven R Goldsmith
May 26, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Marek J Mazur, Raymond L Heilman
Jul 23, 2005·Current Heart Failure Reports·Guido Boerrigter, John C Burnett
Sep 13, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Nataliya V SolenkovaJames M Downey
Apr 13, 2006·Current Opinion in Nephrology and Hypertension·Michael G ShlipakMark J Sarnak
Jul 4, 2006·Physiological Reviews·Volker VallonHartmut Osswald
Aug 16, 2006·Annals of Internal Medicine·Michael G ShlipakDavid S Siscovick
Aug 17, 2006·Shock·Ronald J TrofA B Johan Groeneveld
Apr 28, 2007·Contributions to Nephrology·Prasad Devarajan
May 1, 2007·Hypertension in Pregnancy : Official Journal of the International Society for the Study of Hypertension in Pregnancy·Darcy B CarrThomas R Easterling
Dec 25, 2007·Nature Medicine·Lane BekarMaiken Nedergaard
May 10, 2008·European Journal of Pharmacology·Joanna ListosSylwia Fidecka
Jun 26, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Simin NamvarMaryam Zeraati
Sep 15, 2009·Circulation. Heart Failure·G Michael FelkerUNKNOWN Heart Failure Clinical Research Network Investigators

❮ Previous
Next ❯

Citations

Oct 26, 2013·Current Heart Failure Reports·Guido BoerrigterHarald Lapp
Oct 12, 2010·The New England Journal of Medicine·Barry M MassieUNKNOWN PROTECT Investigators and Committees
Nov 23, 2012·Kidney & Blood Pressure Research·Markus L AlterBerthold Hocher
Dec 3, 2014·European Journal of Medicinal Chemistry·Maria Paola GiovannoniClaudia Vergelli
Aug 31, 2010·Heart Failure Reviews·Amir Kazory, Edward A Ross
May 10, 2011·Heart Failure Reviews·Branko BraamCarlo Gaillard
Sep 3, 2010·Expert Opinion on Pharmacotherapy·Christopher R Ensor, Stuart D Russell
Jul 2, 2010·Kidney International·Berthold Hocher
Nov 22, 2011·Seminars in Nephrology·D Craig Brater
Oct 4, 2011·Journal of Cardiac Failure·Paul J GaliwangoJohn S Floras
Jul 14, 2010·Cardiology Clinics·Suneel M Udani, Jay L Koyner
Sep 9, 2010·European Journal of Heart Failure·Piotr PonikowskiMarco Metra
Dec 21, 2014·Purinergic Signalling·Geoffrey Burnstock, Amir Pelleg
May 27, 2014·Inflammatory Bowel Diseases·Fernando Ochoa-CortesFievos L Christofi
May 23, 2015·The Cochrane Database of Systematic Reviews·Vijaya M MusiniCiprian D Jauca
Feb 22, 2021·Cellular Signalling·Samantha M McNeillLauren T May

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.